新浪登录
腾讯登录Biocept与ACPN合作推广肿瘤无创检测技术
| 导读 | 循环肿瘤细胞(CTCs)检测公司Biocept 今天宣布， 该公司将为美国优选健康支持商网络（America's Choice Provider Network. ACPN）的优选医疗机构保险 (Preferred Provider Organization，PPO)会员提供其公司专有的液体活检肿瘤诊断。 |
循环肿瘤细胞(CTCs)检测公司Biocept 今天宣布， 该公司将为美国优选健康支持商网络（America's Choice Provider Network. ACPN）的优选医疗机构保险 (Preferred Provider Organization，PPO)会员提供其公司专有的液体活检肿瘤诊断。
基于循环肿瘤细胞和DNA技术，圣地亚哥的Biocept公司为临床医生提供了多种肿瘤病人活体肿瘤检测备选方案。该公司的肿瘤血液测试技术也作为一种无创的临床肿瘤检测技术得到了广泛的应用。公司得到CLIA和CAP认证后该测试正式投入使用。目前，Biocept公司正着手在接下来的几个月内陆续推出得到CLIA认证的乳腺癌、肺癌、胃癌、前列腺癌、结肠癌、和其他实体肿瘤的检测服务。
Biocept高级战略主管Amy McNeal在声明中表示：“通过这次与ACPN的合作，我们将额外为1900万美国人提供肿瘤液体活检服务，使他们可以避免组织活检产生的额外手术，降低检测成本的同时提高检测结果的精度。”
Biocept公司是一家坐落在加利福尼亚圣地亚哥的肿瘤分子诊断公司，专门从事循环肿瘤细胞(CTC)和生物标志物的检测与分析。致力于促进肿瘤诊断技术发展，提高癌症诊断效率。利用专利和创新技术为临床病人提供肿瘤诊断服务，为检测实验室、学术机构、研究机构、生物制药公司以及临床试验公司提供技术支持。（转化医学网360zhyx.com）
以上为转化医学网原创翻译整理。如需转载，请联系 info@360zhyx.com 。
转化医学网推荐的新闻阅读：
Biocept today announced that its proprietary liquid biopsy oncology diagnostics will be offered to participants in preferred provider organization America's Choice Provider Network.San Diego-based Biocept's circulating tumor cell- and DNA-based technology gives clinicians an alternative for testing patients when a tumor biopsy is not adequate or practical. The firm's blood-based tests are also used by physicians to monitor a patient's treatment in a non-invasive manner. The tests are performed at the firm's CLIA-certified and CAP-accredited laboratory. Currently, Biocept offers tests for breast, lung , and gastric cancer. It said it plans to introduce additional CLIA-validated tests for lung, prostate, colorectal, breast and other solid tumors in the coming months.
"Through this collaboration with ACPN, we have expanded access to liquid biopsy to 19 million Americans, giving them an option to avoid additional surgeries for a tissue biopsy, thus reducing costs while improving outcomes,” Amy McNeal, Biocept senior director of strategic reimbursement, said in a statement.
Biocept, Inc. is a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and biomarker analysis, headquartered in San Diego, California.
Our mission is to improve outcomes for cancer patients by advancing oncology diagnostics.
We utilize patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. Additionally, we offer services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support.
还没有人评论，赶快抢个沙发